2002 Healthcare: Global Preference
10 Aug 2005
Drug firms are boosting their reputations by preferential pricing, writes Mary Cowlett
Click
to remove filters
The healthcare sector remained largely buoyant in the face of significant changes to the industry...of the factors shaping the healthcare agenda in the past 12 months. As the industry explored ways to get to grips with the challenges, the sector remained resilient. The top of the 2011 healthcare league table remained largely ... change in the top five results from the absence of FD Healthcare, which declined to post figures ...
Drug firms are boosting their reputations by preferential pricing, writes Mary Cowlett
PRWeek's first ever roundtable on healthcare PR drew leading industry figures - from both agencies
Pharma firms are unhappy with potential new disclosure rules, writes Adam Hill
Almost 70 per cent of the top 25 recorded fee income growth over the past year
Healthcare agencies are adapting to the needs of a globalised industry by broadening
Research shows that GPs value creative PR and accurate sales-force delivery from pharma firms, finds Mark Johnson
Cardiff University professor Julie Williams' research uncovered five new genes, helping pinpoint what is going wrong in the brains of Alzheimer's sufferers. The university's PR team wanted to secure worldwide coverage of her findings.
Making up the NHS jigsaw Understanding the bureaucracies of the NHS beast can be a difficult task for agencies, but it isn't impossible, says Andrew Harrison
Time to build biotech trust Honesty about the potential of their products will ensure biotech firms receive the support of investors, says Chris Gardner